EVIVE Biotechnology: Clinical Trials

11 trials sponsored by EVIVE Biotechnology, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 1 terminated, 1 unknown, 1 withdrawn. 6 Phase 2, 4 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 26Completed 4, Terminated 1, Withdrawn 1
Phase 14Completed 3, Unknown 1
Phase 33Completed 3

Follow EVIVE Biotechnology: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of F-652 in Subjects With Corona Virus Disease 2019 (COVID-19) Pneumonia
F-652, Placebo - COVID-19 Pneumonia
Phase 2WithdrawnEVIVE Biotechnology2022-04-082023-10-02
Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19
F-652, Placebo - Covid19
Phase 2TerminatedEVIVE Biotechnology12021-01-262023-12-21
Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma
Recombinant Anti-CD19m-CD3 Antibody Injection - Relapsed or Refractory B-cell Lymphoma
Phase 1UnknownEVIVE Biotechnology542019-09-152019-08-14
Study to Compare the Efficacy and Safety of F-627 and GRAN®
F-627, GRAN® - Breast Cancer, Neutropenia
Phase 3CompletedEVIVE Biotechnology2422018-04-122025-04-20
Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
F-627, Neulasta - Breast Cancer, Neutropenia
Phase 3CompletedEVIVE Biotechnology3932018-04-122023-07-03
Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
F-627, Placebo - Breast Cancer, Neutropenia
Phase 3CompletedEVIVE Biotechnology1222016-08-012021-05-05
Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD
Recombinant Human Interleukin-22 IgG2-Fc (F-652), Systemic Corticosteroids - Acute Graft vs Host Disease
Phase 1 / Phase 2CompletedEVIVE Biotechnology302016-05-122021-07-22
A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.
F-627, Filgrastim - Neutropenia
Phase 2CompletedEVIVE Biotechnology1382014-07-032018-02-23
A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
F-627 240 μg/kg, F-627 320 μg/kg - Neutropenia
Phase 1 / Phase 2CompletedEVIVE Biotechnology152014-02-252019-11-21
Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
F-627, EC regimen - Neutropenia, Breast Cancer
Phase 1CompletedEVIVE Biotechnology182012-12-012024-02-23
Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
F-627, Neulasta® (pegfilgrastim) - Breast Cancer, Neutropenia
Phase 2CompletedEVIVE Biotechnology2322012-06-012018-10-03

Conditions studied

Neutropenia (7)  ·  Breast Neoplasms (5)  ·  COVID-19 (1)  ·  Lymphoma, B-Cell (1)  ·  Recurrence (1)

Interventions

eflepedocokin alfa (3)  ·  Filgrastim (2)  ·  pegfilgrastim (2)  ·  EC regimen (1)  ·  Interleukin-22 (1)

Countries

United States (5)  ·  China (3)

Top investigators

Junning Cao, Professor (2)  ·  Christine M Bojanowski, MD (1)  ·  Doris Ponce, M.D. (1)  ·  Jin Li, Professor (1)  ·  John Glaspy, MD (1)  ·  Kevin F Dreyer (1)  ·  Song Yuqin, Doctor (1)  ·  Zhimin Shao, Doctor (1)

Results publications

PMID 36399701, PMID 38103088, PMID 38194162, PMID 39272058, PMID 41066031